HLB Pharmaceutical Co. Ltd (047920) - Net Assets
Based on the latest financial reports, HLB Pharmaceutical Co. Ltd (047920) has net assets worth ₩120.95 Billion KRW (≈ $81.97 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩167.93 Billion ≈ $113.80 Million USD) and total liabilities (₩46.98 Billion ≈ $31.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 047920 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩120.95 Billion |
| % of Total Assets | 72.03% |
| Annual Growth Rate | 37.51% |
| 5-Year Change | 160.86% |
| 10-Year Change | 855.92% |
| Growth Volatility | 59.42 |
HLB Pharmaceutical Co. Ltd - Net Assets Trend (2014–2024)
This chart illustrates how HLB Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 047920 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for HLB Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual net assets of HLB Pharmaceutical Co. Ltd from 2014 to 2024. For live valuation and market cap data, see 047920 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩116.40 Billion ≈ $78.88 Million |
+32.04% |
| 2023-12-31 | ₩88.15 Billion ≈ $59.74 Million |
+2.59% |
| 2022-12-31 | ₩85.93 Billion ≈ $58.23 Million |
+9.62% |
| 2021-12-31 | ₩78.38 Billion ≈ $53.12 Million |
+75.66% |
| 2020-12-31 | ₩44.62 Billion ≈ $30.24 Million |
+157.06% |
| 2019-12-31 | ₩17.36 Billion ≈ $11.76 Million |
+2.12% |
| 2018-12-31 | ₩17.00 Billion ≈ $11.52 Million |
+1.17% |
| 2017-12-31 | ₩16.80 Billion ≈ $11.39 Million |
-11.10% |
| 2016-12-31 | ₩18.90 Billion ≈ $12.81 Million |
+55.20% |
| 2015-12-31 | ₩12.18 Billion ≈ $8.25 Million |
+152.94% |
| 2014-12-31 | ₩4.81 Billion ≈ $3.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to HLB Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 335.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩1.97 Billion | 1.69% |
| Common Stock | ₩15.91 Billion | 13.67% |
| Other Components | ₩98.52 Billion | 84.64% |
| Total Equity | ₩116.40 Billion | 100.00% |
HLB Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of HLB Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai KEN Tools Co Ltd
SHE:300126
|
$364.72 Million |
|
Shenzhen Maxonic Auto Control
SHE:300112
|
$364.81 Million |
|
Gigastorage Corp
TW:2406
|
$364.83 Million |
|
Lingnan Landscape Co Ltd
SHE:002717
|
$364.91 Million |
|
Hellenic Exchanges - Athens Stock Exchange SA
AT:EXAE
|
$364.46 Million |
|
Oyak Yatirim Menkul Degerler AS
IS:OYYAT
|
$364.18 Million |
|
Regulus Resources Inc
V:REG
|
$363.97 Million |
|
IMC SA
WAR:IMC
|
$363.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HLB Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 88,153,400,350 to 116,401,739,000, a change of 28,248,338,650 (32.0%).
- Net income of 2,019,777,730 contributed positively to equity growth.
- Share repurchases of 1,282,527,270 reduced equity.
- New share issuances of 1,282,527,270 increased equity.
- Other factors increased equity by 26,228,560,920.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩2.02 Billion | +1.74% |
| Share Repurchases | ₩1.28 Billion | -1.1% |
| Share Issuances | ₩1.28 Billion | +1.1% |
| Other Changes | ₩26.23 Billion | +22.53% |
| Total Change | ₩- | 32.04% |
Book Value vs Market Value Analysis
This analysis compares HLB Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.27x to 4.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1596.16 | ₩16400.00 | x |
| 2017-12-31 | ₩1344.92 | ₩16400.00 | x |
| 2018-12-31 | ₩1227.52 | ₩16400.00 | x |
| 2019-12-31 | ₩1253.55 | ₩16400.00 | x |
| 2020-12-31 | ₩2125.79 | ₩16400.00 | x |
| 2021-12-31 | ₩3003.52 | ₩16400.00 | x |
| 2022-12-31 | ₩3083.13 | ₩16400.00 | x |
| 2023-12-31 | ₩2908.18 | ₩16400.00 | x |
| 2024-12-31 | ₩3840.10 | ₩16400.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HLB Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.47%
- • Asset Turnover: 0.87x
- • Equity Multiplier: 1.36x
- Recent ROE (1.74%) is above the historical average (-27.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 6.33% | 1.77% | 0.80x | 4.45x | ₩-176.84 Million |
| 2015 | -19.42% | -13.35% | 0.71x | 2.04x | ₩-3.58 Billion |
| 2016 | 3.06% | 2.84% | 0.49x | 2.18x | ₩-1.31 Billion |
| 2017 | -32.42% | -35.01% | 0.39x | 2.37x | ₩-7.13 Billion |
| 2018 | -41.53% | -34.37% | 0.56x | 2.14x | ₩-8.76 Billion |
| 2019 | 2.72% | 1.31% | 0.78x | 2.67x | ₩-1.26 Billion |
| 2020 | -167.72% | -184.47% | 0.36x | 2.50x | ₩-79.30 Billion |
| 2021 | -16.87% | -21.04% | 0.49x | 1.63x | ₩-21.06 Billion |
| 2022 | -13.71% | -10.96% | 0.76x | 1.65x | ₩-20.37 Billion |
| 2023 | -22.04% | -14.29% | 0.96x | 1.60x | ₩-28.24 Billion |
| 2024 | 1.74% | 1.47% | 0.87x | 1.36x | ₩-9.62 Billion |
Industry Comparison
This section compares HLB Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $555,313,617,248
- Average return on equity (ROE) among peers: 2.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HLB Pharmaceutical Co. Ltd (047920) | ₩120.95 Billion | 6.33% | 0.39x | $364.53 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $110.26 Million |
| Yuhan Corp. (000100) | $2.01 Trillion | 4.74% | 0.23x | $4.32 Billion |
| Yuhan Corp Preferred (000105) | $2.15 Trillion | 3.29% | 0.37x | $56.81 Million |
| Yuyu Pharma (000220) | $90.54 Billion | 5.22% | 0.52x | $45.40 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.61 Million |
| Yuyu Pharma Inc (000227) | $123.37 Billion | -4.85% | 0.58x | $43.13 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $68.95 Million |
| Samil Pharm (000520) | $62.27 Billion | 1.26% | 1.95x | $128.33 Million |
| Donga Socio Holdings (000640) | $534.48 Billion | 0.32% | 1.02x | $418.42 Million |
| Jw Pharmac (001060) | $170.25 Billion | 0.00% | 2.92x | $465.32 Million |
About HLB Pharmaceutical Co. Ltd
HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, anti… Read more